Both Gramatzki et al. [62] and Johnson et al. [61] agreed that the main reason anti-VEGF antibody drugs do not work very well in GBM is because they involves complex gene mutations, but the mechanism is still unclear. This evidence concerns the gene VEGFA and glioblastoma.